Form 4 for HALO HALOZYME THERAPEUTICS, INC.
Accepted 2021-08-10 00:00:00 ET · period of report 2021-08-10 · accession 0001179110-21-008095 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-08-10 | 2021-08-10 | HALO | Torley Helen | Pres, CEO, Dir | S - Sale+OE | $41.11 | -50.0K | 539.1K | -8% | -$2.06M |
| D | 2021-08-10 | 2021-08-10 | HALO | Torley Helen | Pres, CEO, Dir | M - OptEx | $14.66 | +50.0K | 587.2K | +9% | +$733.0K |
| D | 2021-08-10 | 2021-08-10 | HALO | Torley Helen | Pres, CEO, Dir | M - OptEx | $14.66 | -50.0K | 300.0K | -14% | -$733.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-10 | S | D | 500 | $44.91 | 538,208 | D | — | — | (F6) Represents a weighted average sales price per share. These shares were sold at prices ranging from $44.76 to $45.02. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 2 | Common | Common Stock | 2021-08-10 | S | D | 25,138 | $40.42 | 562,022 | D | — | — | (F2) Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.92 to $40.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 3 | Common | Common Stock | 2021-08-10 | S | D | 21,914 | $41.47 | 540,108 | D | — | — | (F3) Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.98 to $41.97. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 4 | Common | Common Stock | 2021-08-10 | S | D | 1,048 | $46.11 | 537,160 | D | — | — | |
| 5 | Common | Common Stock | 2021-08-10 | M | A | 50,000 | $14.66 | 587,160 | D | — | — | |
| 6 | Common | Common Stock | 2021-08-10 | S | D | 400 | $43.26 | 538,708 | D | — | — | (F5) Represents a weighted average sales price per share. These shares were sold at prices ranging from $43.17 to $43.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 7 | Common | Common Stock | 2021-08-10 | S | D | 1,000 | $42.64 | 539,108 | D | — | — | (F4) Represents a weighted average sales price per share. These shares were sold at prices ranging from $42.07 to $42.99. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 8 | Derivative | Option to Purchase Common Stock | 2021-08-10 | M | D | 50,000 | $14.66 | 300,000 | D | $14.66 · — to 2024-01-06 | 50,000 Common Stock | (F7) Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014. |